Loading
Vaxcyte, Inc. Stock: price and insider trades · United States
Vaxcyte, Inc.: what insiders have been doing
Every trade that managers of Vaxcyte, Inc. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Vaxcyte, Inc. logged 75 filings by 15 insiders.
There is no open-market purchase to report; the filings show 27 sales worth €4.0M by 5 insiders. The totals exclude 1 filing filed without an amount. The largest single trade was a sale of €811k by Dhaliwal Harpreet S., published on 5 August 2026, equal to 0.011% of the market capitalisation.
Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
With 75 filings in twelve months, the company is more active than the median of 19 filings across the 5,811 companies we follow on the same exchange. Our records for Vaxcyte, Inc. go back to 2021, with no purchases and 76 sales on the open market in total. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -766.6 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
334
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€13M
76 ops. · all time
Who traded when
BuySaleJim Wassil13 sales
Grant Pickering10 sales
Andrew Guggenhime5 sales
Elvia Cowan3 sales
Harpreet S. Dhaliwal2 sales
Analyst consensus: bullish or bearish?
Analysts rate Vaxcyte, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$117.30.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$65.27
Analyst consensus
10 analystsStrong buy
US$75.00Target US$117.30(+80%)US$163.00
Income statement
EBITDA-US$898.8M
Net income-US$766.6M0.0% margin
Valuation
PER (forward)-9.2x
P/Book3.4x
Beta1.23
Balance sheet & cash
Market capUS$10.3B
Total debtUS$117.5M
Free Cash Flow-US$712.6M
Debt / Equity4%
Profitability & ownership
ROE-36.5%
ROA-22.6%
% insiders0.5%
% institutions110.9%
Last declaration on 7 October 2026
Declarations334 total
18,000 shares@ US$5.350.0009% mcap1.9% of flowCommon StockSEC:0001813798-26-000023:0
19,000 shares@ US$25.920.0045% mcap14.9% of flowCommon StockSEC:0001960048-26-000013:0
19,000 shares@ US$86.740.015% mcap58.8% of flowCommonSEC144:0001969223-26-001059
18,000 shares@ US$86.740.014% mcap32.2% of flowCommonSEC144:0001969223-26-001058
2,155 shares@ US$56.6540.0014% mcap3.7% of flowCommon StockSEC:0001813798-26-000021:1
2,250 shares@ US$5.350.0001% mcap0.4% of flowCommon StockSEC:0001813798-26-000021:0
95 shares@ US$57.0940.0001% mcap0.2% of flowCommon StockSEC:0001813798-26-000021:2
2,250 shares@ US$56.730.0015% mcap4.0% of flowCommonSEC144:0001969223-26-001049
1,334 shares@ US$59.990.0009% mcap2.6% of flowCommonSEC144:0001969223-26-001012
52,632 shares0Common StockSEC:0002151661-26-000004:0
1,327 shares@ US$60.360.0009% mcap6.7% of flowCommon StockSEC:0001960048-26-000011:0
7,651 shares@ US$60.360.0054% mcap13.3% of flowCommon StockSEC:0001886794-26-000012:0
7,155 shares@ US$60.360.0051% mcap6.7% of flowCommon StockSEC:0001230724-26-000018:0
17,056 shares@ US$60.360.012% mcap6.2% of flowCommon StockSEC:0001258693-26-000019:0
1,381 shares@ US$61.160.0010% mcap2.7% of flowCommon StockSEC:0001813798-26-000019:0
5,459 shares@ US$60.360.0039% mcap10.5% of flowCommon StockSEC:0001813798-26-000019:1
1,334 shares@ US$59.5210.0009% mcap2.5% of flowCommon StockSEC:0001813798-26-000019:2
1,381 shares@ US$59.730.0010% mcap2.6% of flowCommonSEC144:0001969223-26-001001
17,000 shares@ US$55.000.011% mcap27.2% of flowCommonSEC144:0001969223-26-000851
17,000 shares@ US$24.790.0050% mcap12.3% of flowCommon StockSEC:0001886794-26-000008:0
10,000 shares@ US$5.350.0006% mcap0.8% of flowCommon StockSEC:0001230724-26-000014:0
6,956 shares@ US$53.7610.0044% mcap5.8% of flowCommon StockSEC:0001230724-26-000014:1
3,044 shares@ US$54.1780.0019% mcap2.6% of flowCommon StockSEC:0001230724-26-000014:2
17,000 shares@ US$55.0040.011% mcap27.2% of flowCommon StockSEC:0001886794-26-000008:1
2,250 shares@ US$5.350.0001% mcap0.4% of flowCommon StockSEC:0001813798-26-000015:0
25 of 334 declarations
About Vaxcyte, Inc.
Vaxcyte, Inc. is a clinical-stage biotechnology and vaccine company listed on the NASDAQ under ticker PCVX in the United States. Headquartered in San Carlos, California, the company was incorporated in 2013 under the name SutroVax and adopted the Vaxcyte name in 2020. For investors, it represents a specialized growth biotech with a science-led platform and no meaningful commercial product revenue yet, but with substantial optionality if its late-stage vaccine programs continue to advance successfully.
Vaxcyte’s business is built around its proprietary platform for designing and manufacturing high-fidelity proteins and antigens. The company’s technology originated from cell-free protein synthesis capabilities licensed from Sutro Biopharma and has been further developed internally to support the creation of next-generation vaccines. The strategic focus is on bacterial diseases, especially pneumococcal infections, where the company believes broader serotype coverage and stronger immune responses can create a better product profile than existing vaccines. Its lead asset is VAX-31, a next-generation pneumococcal conjugate vaccine candidate that management describes as the broadest-spectrum PCV in clinical development, with separate programs in adults and infants. VAX-24 has also been an important part of the company’s clinical validation work.
Read moreShow less
In competitive terms, Vaxcyte is trying to challenge established vaccine leaders in a market that is both medically important and commercially attractive. Pneumococcal vaccination is already a well-developed category, dominated by large pharmaceutical companies with approved products and global scale. Vaxcyte’s investment case therefore hinges on differentiation: wider serotype coverage, robust immunogenicity, and a potential best-in-class profile. The company does not yet have a broad commercial footprint; its geographic presence remains primarily U.S.-based, anchored by its California headquarters and an expanding domestic manufacturing strategy.
Recent developments have been especially important. In 2025 and 2026, Vaxcyte reported major clinical progress for VAX-31, including the initiation and enrollment of multiple Phase 3 adult trials and continued advancement of the infant program. The company also published positive clinical data in a respected medical journal, helping strengthen the scientific profile of its lead vaccine candidate. On the manufacturing side, Vaxcyte continued to invest in dedicated production capacity in the United States and in long-term manufacturing agreements, signaling that it is preparing for a potential future commercial launch. Overall, Vaxcyte remains a capital-intensive, high-risk, high-upside biotech story whose valuation will be driven primarily by clinical success, regulatory milestones, and manufacturing execution on the NASDAQ in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
